Pharmaceutical

Valneva hits 2024 sales target but plans lower cash burn in 2025

Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.

Feb 19, 2025 - 06:00
Valneva hits 2024 sales target but plans lower cash burn in 2025
Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.
Read the original article

Tags:

Previous Article

Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use

Next Article

EC conditionally approves MSD’s Welireg for VHL disease and RCC

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Fate Therapeutics makes Bob Valamehr president and CEO

Fate Therapeutics makes Bob Valamehr president and CEO

Dec 3, 2024

ITM-91 by ITM Isotope Technologies Munich for Metastati...

Dec 31, 2024

STAT+: Was Amgen less than forthcoming about FDA’s concerns on its cancer drug?

STAT+: Was Amgen less than forthcoming about FDA’s conc...

Oct 4, 2023